Context Therapeutics amends BioAtla license deal for CT-202 drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. NAVN
10. IBM

Go back to Context Therapeutics amends BioAtla license deal for CT-202 drug
(NASDAQ: BCAB) Delayed: 3.62 --0 (-0%)
Previous Close $3.62    52 Week High $ 
Open $3.62    52 Week Low $ 
Day High $3.62    P/E N/A 
Day Low $3.62    EPS $ 
Volume 15       

(NASDAQ: CNTX) Delayed: 0.63 --0 (-0%)
Previous Close $0.63    52 Week High $ 
Open $0.63    52 Week Low $ 
Day High $0.63    P/E N/A 
Day Low $0.63    EPS $ 
Volume 14,885